Humanized anti-CD73 antibodies
US10822426B2 · kind B2 · utility
2Cited by
2References
27Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 9, 2016 |
| Grant date | Nov 3, 2020 |
| Priority date | — |
| Expiry date | Jan 19, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/916
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.